Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihyper- tensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534 2544. doi: 10.1001/jama.289.19.2534. 39. Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simp- son LM, Levy D, Nwachuku CE, Black HR; ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treat- ment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Valida- tion Study: diagnosis and prognosis. Am Heart J. 2007;153:42 53. doi: 10.1016/j.ahj.2006.10.012. 40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Ef- fects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Out- comes Prevention Evaluation Study Investigators [published cor- rections appear in N Engl J Med. 2000;342:748 and N Engl J Med. 2000;342:1376]. N Engl J Med. 2000;342:145 153. doi: 10.1056/NEJM200001203420301. 41. Flather MD, Yusuf S, K ber L, Pfeffer M, Hall A, Murray G, Torp- Pedersen C, Ball S, Pogue J, Moy L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventric- ular dysfunction: a systematic overview of data from individual patients: ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575 1581. 42. Magid DJ, Shetterly SM, Margolis KL, Tavel HM, O Connor PJ, Sel- by JV, Ho PM. Comparative effectiveness of angiotensin-convert- ing enzyme inhibitors versus beta-blockers as second-line therapy for hypertension. Circ Cardiovasc Qual Outcomes. 2010;3:453 458. doi: 10.1161/CIRCOUTCOMES.110.940874. 43. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parv- ing HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascu- lar outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861 869. doi: 10.1056/NEJMoa011161. 44. 